Clinical Trial Update: The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating intravesical gemcitabine with a one-third dose of Bacillus Calmette-Guérin for superficial bladder cancer has been completed, focusin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• Bacillus Calmette-Guérin (BCG) (Bacillus Calmette-Guérin)
• Gemzar (gemcitabine)

Snippet

Sponsor: A.O.U. Città della Salute e della Scienza | Conditions: Bladder Cancer | Phase 2 | Status: COMPLETED